Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Olema Pharmaceuticals is a biotechnology business based in the US. Olema Pharmaceuticals stocks (OLMA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $25.86 – an increase of 4.48% over the previous week. Olema Pharmaceuticals employs 36 staff and has a market cap (total outstanding stock value) of $1.1 billion.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$28.00|
|52-week range||$19.41 - $60.27|
|50-day moving average||$28.57|
|200-day moving average||$27.70|
|Wall St. target price||$55.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.03|
Note: The dollar amounts in the table below are in Canadian dollars.
|1 week (2021-10-19)||4.48%|
|1 month (2021-09-24)||-1.65%|
|3 months (2021-07-26)||19.50%|
|6 months (2021-04-26)||-9.71%|
|1 year (2020-10-22)||N/A|
|2 years (2019-10-22)||N/A|
|3 years (2018-10-22)||N/A|
|5 years (2016-10-22)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-7.85%|
|Return on equity TTM||-13.13%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
There are currently 2.4 million Olema Pharmaceuticals shares held short by investors – that's known as Olema Pharmaceuticals's "short interest". This figure is 8.3% up from 2.2 million last month.
There are a few different ways that this level of interest in shorting Olema Pharmaceuticals shares can be evaluated.
Olema Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Olema Pharmaceuticals shares currently shorted divided by the average quantity of Olema Pharmaceuticals shares traded daily (recently around 382417.43264659). Olema Pharmaceuticals's SIR currently stands at 6.31. In other words for every 100,000 Olema Pharmaceuticals shares traded daily on the market, roughly 6310 shares are currently held short.
However Olema Pharmaceuticals's short interest can also be evaluated against the total number of Olema Pharmaceuticals shares, or, against the total number of tradable Olema Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Olema Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Olema Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.0976% of the tradable shares (for every 100,000 tradable Olema Pharmaceuticals shares, roughly 98 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Olema Pharmaceuticals.
We're not expecting Olema Pharmaceuticals to pay a dividend over the next 12 months.
Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc.
Stock trading doesn’t have to be expensive. Using Finder’s proprietary algorithm, we’ve identified the best cheap Canadian and US stocks to buy now.Read more…
Steps to owning and managing Cue Health stocks, with 24-hour and historical pricing before you buy.Read more…
Steps to owning and managing ARBK stock, with 24-hour and historical pricing before you buy.Read more…
Everything we know about the AirSculpt Technologies IPO, plus information on how to buy in.
Everything we know about the Candela Medical IPO, plus information on how to buy in.
Everything we know about the Ensemble Health Partners IPO, plus information on how to buy in.
Everything we know about the Fluence Energy IPO, plus information on how to buy in.
Everything we know about the GlobalFoundries IPO, plus information on how to buy in.
Everything we know about the LianBio IPO, plus information on how to buy in.
Everything we know about the Rent the Runway IPO, plus information on how to buy in.
Everything we know about the Solo Brands IPO, plus information on how to buy in.
Everything we know about the Udemy IPO, plus information on how to buy in.
Everything we know about the Arteris IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.